- Genetic Gynecological Testing
- PersonaGene Genetic Panels
- L-asparaginase Assay for Leukemia Patients
- KRAS-BRAF Testing for Colorectal Cancer Mutations
Protein, peptide and immunochemistry services.
We provide consultative oriented services for the isolation, analysis, characterization and production of proteins and peptides.
We’ve improved the most complete pharmacogenetics report in the industry.
The new PersonaGene™ report is our same comprehensive pharmacogenetics panel
with a re-designed report for less paper, better readability, and more personalized information.
We can help you commercialize your ELISA diagnostic
Our staff is qualified to help commercialize your ELISA diagnostic or to develop and validate ELISAs for your specific purpose.
The UroloGene Panel can help personalize his dose.
The UroloGene Panel can provide important information about how a patient metabolizes drugs to help prevent harmful side effects and drug interactions.
AIBioTech is a unique combination of diagnostic laboratory and comprehensive contract research organization. Based on over 20 years of experience with DNA sequencing, assay development and practical research applications, AIBioTech provides medical testing services to physicians as well as research and development services to physicians and life science investigators in clinical practices; biotechnology and pharmaceutical companies; academic institutions and in several different government agencies.
Our scientists are serious researchers who work with top pharmaceutical; biotechnology; and research and development companies to help bring their products from discovery to market. They also develop innovative clinical assays using the latest DNA sequencing technologies to provide medical testing to physicians and patients.
AIBioTech laboratories are certified by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA). Contract research services are offered individually or can be integrated to support product development from discovery to market with full regulatory support under FDA GLP Guidelines 21 CFR 58.